While fellow pharmaceutical executives urged policymakers not to intervene in drug pricing during a Senate Finance Committee hearing Tuesday, Feb. 26, AstraZeneca’s chief executive went the opposite direction.
According to rolling updates from MM&M, Pascal Soriot pleaded with Senators to take action against the drug pricing system.
“We are in a system that used to be fit for purpose and drove enormous savings, but it’s no longer fit for purpose,” he said during the hearing. “It is one of those seituations where nobody in the system can do anything [to] fix it themselves, the government has to step in and fix it.”
To read more on MM&M, click here.